Skip to main content
. 2012 Mar 10;5:135. doi: 10.1186/1756-0500-5-135

Table 1.

Baseline characteristics of patients aged ≥ 65 years (n = 108)

Category n or mean ± SD
Gender (Male/Female) 54/54

Age 68.2 ± 2.8

Body Weight (kg) 58.4 ± 9.5

Body mass index (kg/m2) 23.3 ± 3.0

History of interferon therapy (yes/no) 40/68

History of diabetes mellitus (yes/no) 19/89

History of hypertension (yes/no) 47/61

White blood cells (/mm3) 4909 ± 1332

Red blood cells (× 104/mm3) 436.1 ± 39.8

Hemoglobin (g/dL) 13.8 ± 1.2

Platelets (× 104/mm3) 15.3 ± 3.9

AST (IU/L) 65.2 ± 37.3

ALT (IU/L) 76.0 ± 65.5

AFP (ng/ml) 15.7 ± 31.4

Histology (METAVIR) Fibrosis (1/2/3/4) 22/41/37/8

Histology (METAVIR) Activity (1/2/3) 30/51/27

HCV genotype (1/2) 86/22

Serum HCV RNA (KIU/ml) 1650 ± 1521

Peg-IFN dose (g/kg/week) 1.22 ± 0.32

Total Peg-IFN dose > 80% (yes/no) 63/45

Daily ribavirin dose (mg/kg) 9.58 ± 2.93

Total ribavirin dose > 80% (yes/no) 63/45

Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon